IP Library Granted Patent US 10,787,675
Granted Patent B2
US 10,787,675 · App. 16/739,219 · Granted Sep 29, 2020

Purified synthetic marijuana and methods of treatment by administering same

Inventor: Jonnie R. Williams (Sarasota, FL)
Assignee: Supera Pharmaceuticals, Inc.
C12N15/8243A61K31/352A61K36/185C12N15/8257
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,787,675
App. No.
16/739,219
Granted
Sep 29, 2020
Kind
B2
Abstract

A method of increasing the cannabinoid levels in a genetically modified Cannabis sativa plant includes genetically modifying the plant to induce the overexpression of the gene that controls the expression of tetrahydrocannabinolic acid (THCA) synthase and/or cannabidiolic acid (CBDA) synthase. The overexpression of THCA synthase and CBDA synthase catalyzes an increased synthesis of cannabigerolic acid to tetrahydrocannabinolic acid and cannabidiolic acid, as well as the cannabinoids (3aR)-2,4,4-trimethyl-7-pentyl-3,3a,4,9b-tetrahydrocyclopenta[c]chromen-9-ol and 2-((1R,5R)-3-methyl-5 -(prop-1-en-2-yl)cyclopent-2-en-1-yl)-5-pentylbenzene-1,3-diol. Pharmaceutical compositions comprising the modified cannabinoids produced by the transgenic Cannabis sativa plant or prepared synthetically are used to treat various diseases and conditions.

Claims (11)

1. A compound having the structure:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable vehicle therefor.

3. A pharmaceutical composition of claim 2 which contains an isolated enantiomer having the structure:

4. A pharmaceutical composition of claim 2 which contains an isolated enantiomer having the structure:

5. A pharmaceutical composition of claim 2 which contains a racemic mixture of enantiomers having the structures:

6. A pharmaceutical composition of claim 4 , wherein the pharmaceutically acceptable vehicle is a capsule, tablet, syrup, lozenge, inhaler, e-cigarette, chewable gum, nasal spray, transdermal patch, liquid, transmucosal vehicle, hydrogel, nanosome, liposome, noisome, nanoparticle, nanosphere, microsphere, microparticle, microemulsion, nanosuspension, or micelle.

7. A method of treating an addiction to alcohol, tobacco, opioids, prescription drugs, cocaine, benzodiazepines, amphetamines, hallucinogens, inhalants, phencyclidine, or other illicit drug, the method comprising administering to an individual in need thereof a pharmaceutical composition of claim 6 .

8. A method of treating anxiety comprising administering to an individual in need thereof a pharmaceutical composition of claim 6 .

9. A method of treating depression comprising administering to an individual in need thereof a pharmaceutical composition of claim 6 .

10. A method of treating Alzheimer's disease comprising administering to an individual in need thereof a pharmaceutical composition of claim 6 .

Assignments (7)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE PROPERTY NUMBERS BY REMOVING 10787675 PREVIOUSLY RECORDED AT REEL: 059680 FRAME: 0941. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 20, 2023
From: MYMD PHARMACEUTICALS (FLORIDA), INC.
To: MYMD PHARMACEUTICALS, INC.
Reel/Frame 063695/0448 →
CHANGE OF NAME Recorded Oct 16, 2022
From: MIRA1A THERAPEUTICS, INC.
To: MIRA PHARMACEUTICALS, INC.
Reel/Frame 061685/0537 →
MERGER Recorded Apr 22, 2022
From: MYMD PHARMACEUTICALS (FLORIDA), INC.
To: MYMD PHARMACEUTICALS, INC.
Reel/Frame 059680/0941 →
CHANGE OF NAME Recorded Jan 14, 2022
From: MIRA PHARMACEUTICALS, INC.
To: MIRA1A THERAPEUTICS, INC.
Reel/Frame 058750/0331 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2021
From: WILLIAMS, JONNIE R, SR
To: MIRA PHARMACEUTICALS, INC.
Reel/Frame 057365/0195 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2020
From: SUPERA PHARMACEUTICALS, INC.
To: WILLIAMS, JONNIE R., SR.
Reel/Frame 054051/0340 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2020
From: WILLIAMS, JONNIE R.
To: SUPERA PHARMACEUTICALS, INC.
Reel/Frame 051474/0355 →
Continuity (3)
Division 16612472
Provisional Application 62632448 · Feb 20, 2018
Related Publication 20200155629A1 · May 21, 2020